Top

Published in:

01-09-2017 | Laboratory Investigation

Do race and age vary in non-malignant central nervous system tumor incidences in the United States?

Authors: Haley Gittleman, David J. Cote, Quinn T. Ostrom, Carol Kruchko, Timothy R. Smith, Elizabeth B. Claus, Jill S. Barnholtz-Sloan

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

Epidemiological analyses of many cancers have demonstrated differences in incidence and outcome for patients from different racial backgrounds. The aim of this study was to determine the incidence of non-malignant CNS tumors by race and age to identify incidence variance. Data from the Central Brain Tumor Registry of the United States (CBTRUS) from 2009 to 2013 were used to calculate age-adjusted incidence rates (IR) per 100,000 population and 95% confidence intervals for selected tumors overall, by race, age group, and race stratified by age group. In those aged 0–14 years, Whites had significantly greater IR of neuronal and mixed neuronal-glial tumors (IR = 0.37) compared to Others (IR = 0.26) and Blacks (IR = 0.24). In those 15–39 years, Blacks had significantly greater IR of tumors of the pituitary (IR = 3.80) than Others (IR = 3.29) and Whites (IR = 3.15), and significantly greater IR of grade I meningioma (IR = 1.93) than Whites (IR = 1.59) and Others (IR = 1.21). In those 40 years and older, Blacks had significantly greater IR of grade I meningioma (IR = 19.16) compared to Whites (IR = 15.77) and Others (IR = 15.32), and significantly greater IR of tumors of the pituitary (IR = 10.47) than Others (IR = 5.85) and Whites (IR = 4.99). Others had significantly greater IR of nerve sheath tumors (IR = 4.00) compared to Whites (IR = 3.46) and Blacks (IR = 1.64). The incidence of non-malignant CNS tumors differs significantly by race and age in the USA. These differences may contribute to previously-described health outcome disparities.

Available only for authorised users

Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM (1998) The descriptive epidemiology of craniopharyngioma. J Neurosurg 89:547–551. doi:10.3171/jns.1998.89.4.0547 CrossRefPubMed

Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF (2002) Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 94:1537–1545CrossRefPubMed

Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG (1999) Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro-oncology 1:14–25PubMedPubMedCentral

Jane JA Jr, Laws ER Jr (2001) The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg 193:651–659CrossRefPubMed

Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS (2015) Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-oncology 17:1166–1173. doi:10.1093/neuonc/nov069 CrossRefPubMedPubMedCentral

Rouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS (2016) Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-oncology 18:70–77. doi:10.1093/neuonc/nov249 CrossRefPubMed

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov189 CrossRefPubMedPubMedCentral

Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 16(Suppl 4):iv1–i63. doi:10.1093/neuonc/nou223 CrossRefPubMedPubMedCentral

Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173:655–664. doi:10.1530/eje-15-0189 CrossRefPubMed

10.

Bahemuka M (1988) Worldwide incidence of primary nervous system neoplasms. Geographical, racial and sex differences, 1960–1977. Brain 111(Pt 3):737–755CrossRefPubMed

11.

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. doi:10.1111/j.1365-2265.2009.03667.x CrossRef

12.

Gittleman H, Ostrom QT, Farah PD, Ondracek A, Chen Y, Wolinsky Y, Kruchko C, Singer J, Kshettry VR, Laws ER, Sloan AE, Selman WR, Barnholtz-Sloan JS (2014) Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg 121:527–535. doi:10.3171/2014.5.jns131819 CrossRefPubMed

13.

Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545–553. doi:10.1007/s11102-012-0454-0 CrossRefPubMed

14.

Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-Sloan JS (2015) Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 16(Suppl 10):x1–x36. doi:10.1093/neuonc/nou327 CrossRefPubMed

15.

Preston-Martin S, Lewis S, Winkelmann R, Borman B, Auld J, Pearce N (1993) Descriptive epidemiology of primary cancer of the brain, cranial nerves, and cranial meninges in New Zealand, 1948–88. Cancer Causes Control 4:529–538CrossRefPubMed

16.

Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC (2009) Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987–2005). Cancer Epidemiol Biomarkers Prev 18:121–131. doi:10.1158/1055-9965.epi-08-0679 CrossRefPubMed

17.

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 66:31–42. doi:10.3322/caac.21320 CrossRefPubMed

18.

Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010 doi:10.1016/s0140-6736(14)62038-9 CrossRefPubMed

19.

Haider AH, Scott VK, Rehman KA, Velopulos C, Bentley JM, Cornwell EE 3rd, Al-Refaie W (2013) Racial disparities in surgical care and outcomes in the United States: a comprehensive review of patient, provider, and systemic factors. J Am Coll Surg 216:482–492.e412. doi:10.1016/j.jamcollsurg.2012.11.014 CrossRefPubMed

20.

Hunt B, Balachandran B (2015) Black:White disparities in lung cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 39:908–916. doi:10.1016/j.canep.2015.10.003 CrossRefPubMed

21.

Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38:118–123. doi:10.1016/j.canep.2013.09.009 CrossRefPubMed

22.

Doamekpor LA, Zuckerman DM (2014) Lack of diversity in cancer drug clinical trials may exacerbate racial disparities in mortality rates. Cancer Epidemiol 38:645–646. doi:10.1016/j.canep.2014.06.007 CrossRefPubMed

23.

Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG 2nd, Sloan AE (2007) Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol 85:171–180. doi:10.1007/s11060-007-9405-4 CrossRefPubMed

24.

Curry WT Jr, Barker FG 2nd (2009) Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol 93:25–39. doi:10.1007/s11060-009-9840-5 CrossRefPubMed

25.

Curry WT, Jr., Carter BS, Barker FG, 2nd (2010) Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988–2004. Neurosurgery 66:427–437. doi:10.1227/01.neu.0000365265.10141.8e (discussion 437–428)CrossRefPubMed

26.

Gittleman HR, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, Elder JB, Rosenfeld SS, Selman WR, Sloan AE, Barnholtz-Sloan JS (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121:102–112. doi:10.1002/cncr.29015 CrossRefPubMed

27.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro-oncology 15(Suppl 2):ii1–i56. doi:10.1093/neuonc/not151 CrossRefPubMedPubMedCentral

28.

Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20:E1. doi:10.3171/foc.2006.20.4.E1 CrossRefPubMed

29.

Jorgensen JT, Johansen MS, Ravnskjaer L, Andersen KK, Brauner EV, Loft S, Ketzel M, Becker T, Brandt J, Hertel O, Andersen ZJ (2016) Long-term exposure to ambient air pollution and incidence of brain tumours: The Danish nurse cohort. Neurotoxicology. doi:10.1016/j.neuro.2016.06.003 PubMed

30.

Robertson JT, Gunter BC, Somes GW (2002) Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. Br J Neurosurg 16:562–566CrossRefPubMed

31.

Nuno M, Mukherjee D, Elramsisy A, Nosova K, Lad SP, Boakye M, Yu JS, Black KL, Patil CG (2012) Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. Ann Surg Oncol 19:2657–2663. doi:10.1245/s10434-012-2353-z CrossRefPubMed

32.

Moore SP, Antoni S, Colquhoun A, Healy B, Ellison-Loschmann L, Potter JD, Garvey G, Bray F (2015) Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study. Lancet Oncol 16:1483–1492. doi:10.1016/s1470-2045(15)00232-6 CrossRefPubMed

33.

Jacobs-Wingo JL, Espey DK, Groom AV, Phillips LE, Haverkamp DS, Stanley SL (2016) Causes and Disparities in Death Rates Among Urban American Indian and Alaska Native Populations, 1999–2009. Am J Public Health 106:906–914. doi:10.2105/ajph.2015.303033 CrossRefPubMed

34.

Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 18(Suppl 1):i1–i50. doi:10.1093/neuonc/nov297 CrossRefPubMed

Title: Do race and age vary in non-malignant central nervous system tumor incidences in the United States?
Authors: Haley Gittleman
David J. Cote
Quinn T. Ostrom
Carol Kruchko
Timothy R. Smith
Elizabeth B. Claus
Jill S. Barnholtz-Sloan
Publication date: 01-09-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2543-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Do race and age vary in non-malignant central nervous system tumor incidences in the United States?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors

Retraction Note to: Relationship between inflammatory cytokines and risk of depression, and effect of depression on the prognosis of high grade glioma patients

Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields

Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling

Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma

Aberrant paramagnetic signals outside the tumor volume on routine surveillance MRI of brain tumor patients